Amnesia

The Importance of Testing for Traumatic Brain Injuries Before It's Too Late

Retrieved on: 
Wednesday, October 6, 2021
Dizziness, Neck, Lists of diseases, Diagnosis, Common, Injury, Depression, Physician, Catastrophic injury, Associate, Mood Swings, Slip, Specialization, VNG, Nausea, Brain damage, Head, Insomnia, Hori (slur), Explosion, Amnesia, Cambre, The, Spinal cord injury, Vertigo, TBI, Confusion, Health, Risk, Aphasia, Coma, Brain, Spine, Traumatic brain injury, Headache, Seizure, GLOBE, Meat, Health insurance

ATLANTA, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Traumatic brain injury (TBI) results from an impact to the head.

Key Points: 
  • ATLANTA, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Traumatic brain injury (TBI) results from an impact to the head.
  • Injuries can be mild or more serious and leave bruising, torn tissue, internal/external bleeding or physical damage to the head and/or brain.
  • When involved in an accident that injures the head, neck or spine, gettested for a traumatic brain injury even when there are no physical symptoms.
  • Mild symptoms of a traumatic brain injury include headache, nausea, speech problems, loss of balance, light sensitivity and other sensory problems.

Human Rights Activists in Germany Take to the Streets to Protest Electroshock

Retrieved on: 
Wednesday, October 6, 2021
Information, Patient, Therapy, ECT, Memory, Shock, Multimedia, Scientology status by country, Death, Headache, Disinterest, Citizens Commission on Human Rights, Amazon Fire tablet, Amnesia, Nausea, Torture, Apathy, Mental Health Awareness Month, Freedom, Volunteering, Church, Electroconvulsive therapy, CCHR, Human rights, Confusion, Scientology Network, Psychiatry, Brain, DIRECTV, Apple TV, Electricity, Roku, Pharmaceutical industry, Mobile phone

LOS ANGELES, Oct. 5, 2021 /PRNewswire/ --At a rally and demonstrationin the heart of Frankfurt, Germany, Citizens Commission on Human Rights (CCHR) demanded transparency and an end to electroshock (ECT) in the country.

Key Points: 
  • LOS ANGELES, Oct. 5, 2021 /PRNewswire/ --At a rally and demonstrationin the heart of Frankfurt, Germany, Citizens Commission on Human Rights (CCHR) demanded transparency and an end to electroshock (ECT) in the country.
  • Several people attending the rally expressed their shock that electroshock is still practiced in Germany.
  • Volunteers dragged a giant gravestone down Kaiserstrasse that bore the inscription, "In memory of 60,078 deaths in German psychiatric hospitals 1991-2017."
  • Citizens Commission on Human Rights is a nonprofit charitable mental health watchdog established by the Church of Scientology in 1969, dedicated to eradicating psychiatric abuses and ensuring patient protections.

University of Rochester Researchers Link Chemo Brain to Lymphoma; Exercise Might Help Some Cancer Patients

Retrieved on: 
Tuesday, October 5, 2021
Attention, News, Strathcona County, Breast, Man, Exercise, National Cancer Institute, Memory, Cancer, Government budget balance, Solution, Survivor, Attention deficit hyperactivity disorder, Multimedia, Patient, Cognition, University of Rochester Medical Center, JNCI, Lymphoma, University, Woman, Control, Disease, Risk, Journal, Research, Brain, NCI, Amnesia, Journal of the National Cancer Institute, Breast cancer, American Journal of Clinical Oncology, Medical imaging, Toy

Separately, investigators found that routine exercise prior to chemotherapy might prevent chemo brain among women with breast cancer, according to two recently published studies by the Wilmot Cancer Institute at the University of Rochester Medical Center .

Key Points: 
  • Separately, investigators found that routine exercise prior to chemotherapy might prevent chemo brain among women with breast cancer, according to two recently published studies by the Wilmot Cancer Institute at the University of Rochester Medical Center .
  • The National Cancer Institute estimates there are 17 million survivors today and expect 22 million by 2030.
  • Until now, most chemo brain research was focused on solid tumors, such as breast and prostate cancer.
  • A primary goal is to find ways to help older adults, who in general have the highest risk for cancer.

Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and TransCon™ CNP at the American Society for Bone & Mineral Research 2021 Annual Meeting

Retrieved on: 
Thursday, September 30, 2021
Kidney, Degenerative disease, Achondroplasia, Standard of care, CNP, Patient, Hearing loss, Annual report, HP, Hormone, FGFR3, U.S. Securities and Exchange Commission, Parathyroid hormone, Autoinjector, Hypoesthesia, Amnesia, Otitis media, Sleep apnea, Autosome, Growth, Paresthesia, PTH, Disease, Risk, Science, COVID-19, Southern Transcon, Judgement, Technology, Research, Brain, Calcitriol, Forward-looking statement, Safety, Spine, Exocrine gland, Quality of life, Dwarfism, Investment, Brachycephaly, Headache, Mutation, Eye, SEC, Pharmaceutical industry

COPENHAGEN, Denmark, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company using its innovative TransCon technologies to potentially create new treatments to make a meaningful difference in patients’ lives, today announced presentations featuring new data about its investigational TransCon PTH product candidate at the American Society for Bone & Mineral Research (ASBMR) 2021 Annual Meeting, being held October 1-4 virtually and in-person in San Diego. Presentations will also include an overview of baseline demographics from the Ascendis Pharma-sponsored natural history study of children with achondroplasia.

Key Points: 
  • In the short term, symptoms include weakness, severe muscle cramps (tetany), abnormal sensations such as tingling, burning and numbness (paresthesia), memory loss, impaired judgment and headache.
  • HP remains among the few hormonal insufficiency states without an approved replacement therapy that restores the missing hormone at physiologic levels.
  • As a result, patients with HP have an estimated 4-fold to 8-fold greater risk of renal disease compared to healthy controls.
  • SKYTROFA, Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma Group.

PharmaTher Retains Former FDA Psychiatry Division Director Dr. Thomas Laughren as Regulatory Affairs Advisor

Retrieved on: 
Wednesday, September 29, 2021
Ketamine, OTCQB, Center for Drug Evaluation and Research, Research, Review, Investigational New Drug, Compliance, Massachusetts, Hospital, Holding, Depression, FDA, CSE, Regulatory affairs, MD, Division, Lists of diseases, Amnesia, Hallucination, Company, Center, IND, Betaine, Confusion, Trial of the century, Mental health, Massachusetts General Hospital, GLOBE, Pharmaceutical industry

TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that Dr. Thomas Laughren has been retained by PharmaTher as a Regulatory Affairs Advisor.

Key Points: 
  • TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that Dr. Thomas Laughren has been retained by PharmaTher as a Regulatory Affairs Advisor.
  • Dr. Laughren will advise on regulatory matters as it pertains to KETABET, the Companys patented combination formulation of FDA-approved ketamine and betaine, as a potential next-generation treatment for neuropsychiatric disorders.
  • Dr. Thomas Laughren formerly served as the Director for the Division of Psychiatry Products, Center for Drug Evaluation and Research at the FDA where he served for 29 years.
  • Fabio Chianelli, Chief Executive Officer of PharmaTher, said, We are pleased to have Dr. Laughren as a regulatory advisor to support our clinical and commercial initiatives with KETABET in depression and other neuropsychiatric disorders.

Sunrise Senior Living Appoints Mary Kay Gribbons as Chief Human Resources Officer & Maria Davlantes as Chief Marketing Officer

Retrieved on: 
Monday, September 27, 2021
Health, Consumer, Residential Building & Real Estate, Seniors, Managed Care, Construction & Property, Data science, Northwestern University, American Airlines, CHRO, Plant, BP, Kansas City International Airport, Bachelor of Arts, Sunrise Senior Living, Business administration, Communication studies, Duke University, Culture, Nursing, Bachelor, Chief Dental Officer (Canada), Master of Business Administration, Ownership, Dean Foods, Marketing, Environment, Amnesia, Senior living, Industry, United Kingdom, CMO, TE Connectivity, Company, Growth, Awareness, Leadership, McKinsey & Company, COVID-19, Arco, Callison, Interface, Movement, Quality of life, Alzheimer's disease, Kellogg School, Interface, Inc., Management

Sunrise Senior Living, a leading provider of senior living services, announced today the appointment of Mary Kay (MK) Gribbons as Chief Human Resources Officer (CHRO) and Maria Davlantes as Chief Marketing Officer (CMO).

Key Points: 
  • Sunrise Senior Living, a leading provider of senior living services, announced today the appointment of Mary Kay (MK) Gribbons as Chief Human Resources Officer (CHRO) and Maria Davlantes as Chief Marketing Officer (CMO).
  • Ms. Gribbons brings more than twenty years of experience in human resources and operations across industries with a demonstrated track record of building high-performing cultures that drive results through engagement, ownership, and adaptability.
  • There she led a formal restructuring, developed programs to retain leaders, and enhanced internal communication during a period of intense change.
  • Ms. Gribbons joined the Sunrise team on September 20, and Ms. Davlantes will begin her role on October 11.

Ascendis Pharma A/S Announces Mean Bone Mineral Density (BMD) Data from Phase 2 PaTH Forward Trial Demonstrating Continued Normalization and Stabilization of BMD Z-scores Between 26 and 58 Weeks

Retrieved on: 
Wednesday, September 22, 2021
Kidney, BMD, Degenerative disease, Standard of care, Patient, Annual report, HP, Hormone, U.S. Securities and Exchange Commission, Parathyroid hormone, Autoinjector, Hypoesthesia, Adult, Amnesia, Hypoparathyroidism, Paresthesia, PTH, Disease, Risk, Science, COVID-19, Southern Transcon, Judgement, Technology, Research, Brain, Calcitriol, Forward-looking statement, Safety, Investment, Exocrine gland, Quality of life, Headache, Eye, SEC, Pharmaceutical industry

COPENHAGEN, Denmark, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company using its innovative TransCon™ technologies to potentially create new treatments to make a meaningful difference in patients’ lives, today announced 58-week BMD data from central lab reading in the PaTH Forward Trial, a global phase 2 trial of its investigational product candidate TransCon PTH in adult subjects with hypoparathyroidism (HP).

Key Points: 
  • TransCon PTH has been granted Orphan drug status in the United States, European Union, and Japan.
  • In the short term, symptoms include weakness, severe muscle cramps (tetany), abnormal sensations such as tingling, burning and numbness (paresthesia), memory loss, impaired judgment and headache.
  • HP remains among the few hormonal insufficiency states without an approved replacement therapy that restores the missing hormone at physiologic levels.
  • SKYTROFA, Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma Group.

Odyssey Group International Begins Enrolling Subjects for Phase 1 Clinical Trial to Treat Concussion

Retrieved on: 
Wednesday, September 22, 2021
Odyssey, News, Neurosteroid, Pharmacokinetics, Compliance, OTC, Inflammation, Private Securities Litigation Reform Act, Pathology, Traffic barrier, MD, Concussion, Twitter, Acquisition, Company, Brain, Amnesia, Drug development, Technology, Oxidative stress, Anxiety, GLOBE, Pharmaceutical industry, Medical imaging

The drug candidate PRV-002 is being developed to treat concussion as a novel neurosteroid delivered nasally.

Key Points: 
  • The drug candidate PRV-002 is being developed to treat concussion as a novel neurosteroid delivered nasally.
  • Odysseys Phase 1 clinical trial status can be viewed at www.clinicaltrials.gov.
  • The most tolerated dose will be used in the subsequent trials to determine efficacy, commented Jacob VanLandingham, Executive VP of Drug Development of Odyssey Group International.
  • Odyssey screening and enrollment of subjects coincides with the completion of their Phase 1 clinical batch of PRV-002.

Oryzon Announces $1 Million Grant From Kabuki Syndrome Philanthropists to Support a Precision Medicine Phase I/II Trial With Vafidemstat

Retrieved on: 
Tuesday, September 21, 2021
ISIN, Human, Person, Ageing, Spanish, Degenerative disease, AD, Communication, KSF, Johns Hopkins University, Genomics, Kabuki syndrome, HOPE, Chromatin, Safety, EMA, Neuron, Boston, ORY, Animal, Public expenditure, Moderate, Gene, Mercado, Amnesia, CEO, MS, Government budget balance, KKI, ESCAPE, Birth, Prospectus, Borderline personality disorder, CNS, Mouse, Clinical trial, Gene expression, Patient, Sale, FDA, CNMV, Neuroinflammation, Hospital, EVOLUTION, Aggression, Forward-looking statement, Lists of diseases, Time, Multiple sclerosis, LSD1, Kennedy Krieger Institute, GLOBE, Hippocampus, KMT2D, Hope, Central nervous system disease, Syndrome, Mission statement, COVID-19, Prevalence, CSF, Research, Quality of life, Schizophrenia, Pharmaceutical industry, Medical device

The grant was awarded by a patient family whose other philanthropic endeavors include founding the Roya Kabuki clinic at Boston Childrens Hospital and sitting on the board of the Kabuki Syndrome Foundation (KSF).

Key Points: 
  • The grant was awarded by a patient family whose other philanthropic endeavors include founding the Roya Kabuki clinic at Boston Childrens Hospital and sitting on the board of the Kabuki Syndrome Foundation (KSF).
  • The Kabuki Syndrome Foundation is proud to partner with Oryzon and key opinion leaders to further our mission of advocating for the advancement of research and therapeutic treatments.
  • Currently, vafidemstat is in two Phase IIb trials in borderline personality disorder (PORTICO) and in schizophrenia patients (EVOLUTION).
  • The company is also deploying a CNS precision medicine approach with vafidemstat in genetically-defined patient subpopulations of certain CNS disorders.

Right at Home Says Families Are the Key to a Dementia-Friendly Future

Retrieved on: 
Monday, September 20, 2021
Dementia, Music, Memory, Parent, Health, Grandparent, National Institute on Aging, Singing, Alzheimer's disease, Disability, Haynes, Home, Amnesia, Personality, Program, Socialization, Family, Awareness, Disease, Adult, National Institute, Right at Home, Cat cognitive support diets, Toy, Residential care

"More and more, we're seeing that intergenerational relationships are mutually beneficial and can have dramatic effects on health."

Key Points: 
  • "More and more, we're seeing that intergenerational relationships are mutually beneficial and can have dramatic effects on health."
  • Founded in 1995, Right at Home offers in-home care to seniors and adults with disabilities who want to live independently.
  • Right at Home's global office is based in Omaha, Nebraska, with more than 600 franchise locations in the U.S. and seven other countries.
  • For more information on Right at Home, visit www.rightathome.net or read the Right at Home blog at www.rightathome.net/blog .